Cargando…
Safety and efficacy of rituximab treatment for vasculitis in hepatitis B virus-associated type II cryoglobulinemia: a case report
INTRODUCTION: Systemic B-cell depletion and clinical remission of the systemic effects of cryoglobulins have already been achieved using rituximab in hepatitis C virus-positive immunocompetent patients. Conversely, to the best of our knowledge there are no reports in the literature regarding the use...
Autores principales: | Pasquet, Florian, Combarnous, François, MacGregor, Brigitte, Coppere, Brigitte, Mausservey, Christelle, Ninet, Jacques, Hot, Arnaud |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3292813/ https://www.ncbi.nlm.nih.gov/pubmed/22284897 http://dx.doi.org/10.1186/1752-1947-6-39 |
Ejemplares similares
-
Obinutuzumab Rescue in Rituximab Resistant Mixed Cryoglobulinemia
por: Genest, Dominique S., et al.
Publicado: (2021) -
Leukocytoclastic Vasculitis in a Patient with Type 1 Cryoglobulinemia
por: Liu, Paul Y., et al.
Publicado: (2011) -
Treatment of chronic hepatitis C-associated cryoglobulinemia vasculitis at the era of direct-acting antivirals
por: Comarmond, Cloé, et al.
Publicado: (2020) -
Management of mixed cryoglobulinemia with rituximab: evidence and consensus-based recommendations from the Italian Study Group of Cryoglobulinemia (GISC)
por: Quartuccio, Luca, et al.
Publicado: (2022) -
Comparing cases of type I cryoglobulinemia with histopathologic findings of vasculitis
por: Bryan, Jaimie, et al.
Publicado: (2022)